Nanobiotix S.A.

NASDAQ:NBTX

Biotechnology

Healthcare
$27.32 -0.91%

-$0.33 today

Market cap
$1.39B
Beta
0.59
P/E (TTM)
-60.2
EPS (TTM)
-$0.51
52W Low $4.31High $57.14

Volume 0.18M

Average 0.08M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$33.42M

FY 2025 · Annual

Investing Cash Flow

-$578,000.00

FY 2025 · Annual

Financing Cash Flow

$37.42M

FY 2025 · Annual

Cash Flow Statement

EUR
Metric
FY 2021
Dec 2021
FY 2022
Dec 2022
FY 2023
Dec 2023
FY 2024
Dec 2024
FY 2025
Dec 2025
Net Income(47M)(57.04M)(39.7M)(68.13M)(23.96M)
Depreciation & Amortization1.56M1.5M1.51M1.62M1.5M
Deferred Income Tax00003K
Stock-Based Compensation3.2M3.17M3.3M4.3M3.54M
Change in Working Capital(4.7M)(606K)(367K)131K(3.4M)
Accounts Receivables62K(101K)(806K)(2.07M)1.85M
Inventory00000
Accounts Payables00000
Other Working Capital(4.76M)(505K)439K2.2M(5.25M)
Other Non-Cash Items17.07M15.87M22.78M42.53M(11.1M)
Operating Cash Flow(29.87M)(37.1M)(12.48M)(19.55M)(33.42M)
Capital Expenditures(228K)(92K)(328K)(846K)(546K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities(14K)230K(21K)(109K)(40K)
Investing Cash Flow(242K)138K(349K)(955K)(578K)
Debt Repayment(3.74M)(4.74M)(3.62M)(4.16M)38.19M
Common Stock Issued00001.54M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(1.44M)(916K)50.39M(980K)(2.31M)
Financing Cash Flow(5.18M)(5.65M)46.77M(5.14M)37.42M
Effect of Forex Changes64K83K(51K)94K(402K)
Net Change in Cash(35.23M)(42.53M)33.9M(25.55M)3.01M
Free Cash Flow(30.1M)(37.2M)(12.8M)(20.4M)(33.97M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$24.0M
+ D&A$1.5M
+ Stock-Based Comp$3.5M
+ Deferred Tax$3.0K
- Working Capital-$3.4M
- Other Non-Cash-$11.1M
= Operating Cash Flow-$33.4M
- Capex-$546.0K
= Free Cash Flow-$34.0M

Analysis

FY2025 free cash flow is -$34.0M. FCF conversion is 141.8% of net income. Operating cash flow was -$33.4M, with capex of -$546.0K. The largest bridge item is Other Non-Cash at -$11.1M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
6-K6-K filingNov 12, 2026
6-K6-K filingNov 9, 2026
6-K6-K filingOct 26, 2026
6-K6-K filingOct 20, 2026
6-K6-K filingOct 1, 2026

Does NBTX generate free cash flow?

Nanobiotix S.A. (NBTX) generated -$33.97M of free cash flow in fiscal 2025.

How much operating cash flow does NBTX produce?

Operating cash flow was -$33.42M, before capital expenditures of $546,000.00.